Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03357952 | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 10 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT06668792 | An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma(FLAMMINGO) | recruiting | Phase 2 | 100 | BiocadINDUSTRY |
| 1 |
| Feb 4, 2025 |
| clinicaltrials |
| NCT03187223 | Bendamustine and Melphalan in Myeloma(BEB-2) | completed | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06799676 | A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 42 | Fuling ZhouOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT01718743 | Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT05117008 | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma(EMBRACE) | terminated | Phase 2 | 1 | Medical College of WisconsinOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT05427812 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 29 | Ichnos Sciences SAINDUSTRY | 3 | Jan 17, 2025 | clinicaltrials |
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 73 | US Oncology ResearchINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05191472 | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | terminated | Phase 2 | 3 | Alfred Chung, MDOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03773107 | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 12 | Wake Forest University Health SciencesOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04786028 | A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM | active not recruiting | Phase 2 | 72 | Canadian Myeloma Research GroupOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06759181 | Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT01903811 | S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma | completed | Phase 2 | 143 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06744894 | SIL as Maintenance Therapy in Multiple Myeloma | not yet recruiting | Phase 2 | 50 | Navy General Hospital, BeijingOTHER | 0 | Dec 20, 2024 | clinicaltrials |
| NCT00965224 | Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma | completed | Phase 2 | 38 | Zwi BernemanOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06083207 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 116 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 13, 2024 | clinicaltrials |
| NCT05665140 | Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients(ELIAS) | recruiting | Phase 2 / Phase 3 | 100 | University Hopsital Schleswig Holstein Campus LübeckOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02315716 | Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma(Cardamon) | active not recruiting | Phase 2 | 281 | University College, LondonOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02406222 | Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)(MUKseven) | active not recruiting | Phase 2 | 124 | University of LeedsOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT01919619 | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | completed | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04436029 | Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | completed | Phase 2 | 5 | Cartesian TherapeuticsINDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Kathleen DorritieOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT03233776 | Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT(AFFECT-1) | completed | Phase 2 | 9 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04099901 | Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial(AFFECT-2) | completed | Phase 2 | 88 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT01857115 | Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)(wCCyd) | completed | Phase 1 / Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Nov 13, 2024 | clinicaltrials |
| NCT00482261 | A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression | completed | Phase 2 | 150 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT01755975 | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06644443 | BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05299424 | A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 48 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04816526 | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | terminated | Phase 2 | 13 | Cartesian TherapeuticsINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT00747123 | A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma | completed | Phase 2 | 30 | CelgeneINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02375555 | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06581640 | Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 5 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 20 | Sellas Life Sciences GroupINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02002598 | Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 23 | Suzanne Lentzsch, MDOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02542657 | Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 30 | Joseph TuscanoOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02633059 | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03000634 | 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 0 | Sep 5, 2024 | clinicaltrials |
| NCT03267888 | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Emory UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT03225417 | Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | unknown | Phase 1 / Phase 2 | 142 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT04847050 | A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2024 | clinicaltrials |
| NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | completed | Phase 1 / Phase 2 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06505369 | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients(TALTEC) | recruiting | Phase 2 | 50 | North Estonia Medical CentreOTHER | 3 | Jul 17, 2024 | clinicaltrials |
| NCT05050305 | Marizomib Central Nervous System (CNS) | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02654990 | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma(PANORAMA_3) | completed | Phase 2 | 248 | pharmaand GmbHINDUSTRY | 22 | Jul 12, 2024 | clinicaltrials |
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 10, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 4, 2025source: clinicaltrials